Integrated Advisors Network LLC Exelixis, Inc. Transaction History

Integrated Advisors Network LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 16, 2023	SELL	$19.04 - $22.74 $75,036 - $89,618	-3,941 Reduced 25.64%	11,431 $249,000
Q2 2023 Jul 14, 2023	SELL	$18.17 - $20.48 $8,521 - $9,605	-469 Reduced 2.96%	15,372 $293,000
Q1 2023 May 05, 2023	SELL	$16.3 - $19.41 $6,846 - $8,152	-420 Reduced 2.58%	15,841 $307,000
Q4 2022 Feb 02, 2023	BUY	$14.96 - $17.39 $243,264 - $282,778	16,261 New	16,261 $260,000
Q3 2022 Nov 07, 2022	BUY	$15.68 - $22.27 $40,501 - $57,523	2,583 Added 21.66%	14,507 $227,000
Q2 2022 Aug 12, 2022	BUY	$17.44 - $23.16 $7,098 - $9,426	407 Added 3.53%	11,924 $248,000
Q1 2022 May 02, 2022	SELL	$17.03 - $22.67 $16,876 - $22,465	-991 Reduced 7.92%	11,517 $261,000
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $198,126 - $273,675	12,508 New	12,508 $229,000

507

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Integrated Advisors Network LLC, based on Form 13F filings with the SEC.

Stay updated on Integrated Advisors Network LLC with notifications on news.